Francesco Facchinetti
ScholarGPS® ID: 45290379938669
Affiliation History
Field
Medicine
Discipline
Oncology
Top Specialties
Cancer | Lung Cancer | Non-small-cell Lung Carcinoma | Opioid | Blood Plasma | Epidermal Growth Factor Receptor | Neoplasm | Immune Checkpoint | Cancer Immunotherapy | Checkpoint Inhibitor | Hormone | Nivolumab | Thorax | Obesity | Protein Kinase Inhibitor
Metrics Summary
Publication Count
217
Predicted Citations
5,728
Predicted h-index
40
Ranking
Publications and Citation History
Publications based on Top Specialties
Types of Publication
- Publications
- Books
- Patents
- NIH/NSF
Add
Delete
|
---|
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making (journal article) Tumori Journal (2024). |
Journal of Thoracic Oncology, volume 19, issue 1, pages 166-172 (2024). |
Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era (journal article) Journal of Thoracic Oncology, volume 18, issue 9, pages 1118-1120 (2023). |
Discontinuation of immunotherapy over 2 years for patients with non–small cell lung cancer (NSCLC): A search for predictors. (journal article) Journal of Clinical Oncology, volume 41, issue 16_suppl, pages 2661-2661 (2023). |
Non-small-cell lung cancer: how to manage BRAF-mutated disease (journal article) Drugs in Context, volume 12 (2023). |
Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis (journal article) European Journal of Cancer, volume 180 (2023). |
Cancers, volume 14, issue 24, pages 6074- (2022). |
34P Gustave Roussy Match-R study: A descriptive analysis of the molecular target population (journal article) Annals of Oncology, volume 33 (2022). |
Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone Matters (journal article) Journal of Thoracic Oncology, volume 17, issue 6, pages 739-741 (2022). |
Ad Hoc Afatinib in an Eldery Lung Cancer Patient with EGFR Exon 19 Deletion L747-A750>P (journal article) Advances in Respiratory Medicine, volume 90, issue 3, pages 234-235 (2022). |
Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer (journal article) Translational Lung Cancer Research, volume 11, issue 3, pages 381-392 (2022). |
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors (journal article) Tumori Journal, volume 108, issue 1, pages 47-55 (2022). |
JTO Clinical and Research Reports, volume 3, issue 2, pages 100278- (2022). |
Targeted Oncology, volume 17, issue 1, pages 43-51 (2022). |
Translational Lung Cancer Research, volume 11, issue 1, pages 64-74 (2022). |
The efficacy of immune checkpoint inhibitors in thoracic malignancies (journal article) European Respiratory Review, volume 30, issue 162, pages 200387- (2021). |
Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial (journal article) Translational Lung Cancer Research, volume 10, issue 12, pages 4322-4327 (2021). |
Digestive and Liver Disease, volume 53, issue 12, pages 1664-1665 (2021). |
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy (journal article) Current Treatment Options in Oncology, volume 22, issue 11 (2021). |
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy (journal article) Annals of Oncology, volume 32, issue 11, pages 1391-1399 (2021). |